Loading...
Loading...
THMO| Name | Value |
|---|---|
| Revenues | 2,572.0K |
| Cost of Revenue | 1,467.0K |
| Gross Profit | 1,105.0K |
| Operating Expense | 2,150.0K |
| Operating I/L | -1,045.0K |
| Other Income/Expense | -234.0K |
| Interest Income | 0.0K |
| Pretax | -5,182.0K |
| Income Tax Expense | 3,812.0K |
| Net Income/Loss | -5,086.0K |
ThermoGenesis Holdings, Inc. develops and markets automated technologies for cell-based therapies, including the CAR-TXpress platform for CAR-T immunotherapy. Its suite of solutions includes the AXP II Automated Cell Separation System, BioArchive Automated Cryopreservation System, PXP Point-of-Care System, and X-Series products for cell isolation and purification. These products cater to clinical biobanking, point-of-care applications, and immuno-oncology, addressing the critical unmet need for large-scale cellular processing. The company generates revenue through the sale of its automated systems and platforms, which streamline the manufacturing process for cell-based therapies and contribute to advancements in the emerging CAR-T immunotherapy market.
